Multiple myeloma: Every year a new standard?
نویسندگان
چکیده
منابع مشابه
Multiple Myeloma Update
This literature review presents the most recent developments in the management of multiple myeloma, which is characterized by the presence of abnormal plasma cells (myeloma cells) that accumulate into the bone marrow. Aspects related to pathophysiology, clinical manifestations, laboratory, study and treatment are described. These pieces of information are necessary to accomplish a better ...
متن کاملTreatment of Multiple Myeloma
Les traitements classiques de myelome multiple et les schemas differents proposes ont ete mis en revue. La poly chimiotherapie de la maladie avec une com-binaison de cyclophosphamide, B.C.N.U. Alkeran, Perdnisone et Vincristine a donnee une meilleur Resultat ceci surtout dans les formes graves et rapidement progressive de la maladie. D'autres sehemas therapeutiques sont en cours.
متن کامل33 CASES OF MULTIPLE MYELOMA WITH MASSIVE BONE DESTRUCTION: REPORT OF A 10-YEAR STUDY IN NORTHEASTERN IRAN
The author studied 133, 856 admissions over a ten-year period and found 138 cases of primary tumors of bone. Of these only 33 were multiple myeloma. Incidence, clinical manifestation, age, sex and etiology are reported, and the effect of four different chemotherapy regimens are evaluated.
متن کاملThalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.
In this issue of the Journal of Clinical Oncology, Rajkumar et al report on the results of a randomized phase III clinical trial of thalidomide plus dexamethasone compared to high-dose dexamethasone alone in newly diagnosed multiple myeloma. In this study, coordinated by the Eastern Cooperative Oncology Group, 207 patients were randomly assigned to either thalidomide plus dexamethasone or high-...
متن کاملLenalidomide: a new therapy for multiple myeloma.
The last decade has seen rapid evolution in the management of multiple myeloma. Cytogenetic, molecular, and proteomic techniques have led to a better understanding of the pathophysiology and prognostic markers of this heterogeneous malignancy. New immunomodulatory drugs, such as lenalidomide, which interrupt myeloma growth and survival pathways have entered into clinical usage. Combined with de...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hematological Oncology
سال: 2019
ISSN: 0278-0232,1099-1069
DOI: 10.1002/hon.2586